{
    "clinical_study": {
        "@rank": "43464", 
        "arm_group": {
            "arm_group_label": "Synflorix\u2122 cohort", 
            "description": "Only those subjects to whom Synflorix\u2122 will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study."
        }, 
        "brief_summary": {
            "textblock": "This PMS study aims to collect safety and reactogenicity data of Synflorix\u2122 in healthy\n      infants and children of the local population as per the licensing requirement of the Sri\n      Lankan regulatory authority."
        }, 
        "brief_title": "Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix\u2122 Vaccine, in Healthy Infants and Children in Sri Lanka", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Immunisation Against Streptococcus Pneumoniae", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "The participating physicians (investigators) will be asked to enrol only those subjects to\n      whom they administer Synflorix\u2122 in the course of their normal clinical practice according to\n      the locally approved Prescribing Information.\n\n      Since there is lack of clarity regarding the PMS study requirement (both from Regulatory\n      agency and Ethics Committee), it was decided that GSK will submit Local PSURs on a regular\n      basis as desired by Local regulatory agency. The same is communicated to Regulatory agency\n      and if they want something more they are requested to revert back with specific\n      requirements."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes that their parent(s)/ LAR(s) can and will\n             comply with the requirements of the protocol should be enrolled in the PMS study.\n\n          -  Infants aged 6 weeks and above and children.\n\n          -  Written, signed or thumb-printed informed consent obtained from the parent(s)/LAR(s)\n             of the child. Where subject's parent(s)/LAR(s) are illiterate, the consent form will\n             be countersigned by an impartial witness.\n\n        Note: Consent for this PMS study is solely for collection of safety and reactogenicity\n        data and not for vaccination that is per routine practice. Data for demography, medical\n        history and previous vaccination history, and concomitant medication/vaccination will also\n        be collected.\n\n        Exclusion Criteria:\n\n          -  Subjects with contraindications according to the locally approved PI.\n\n          -  Child in care.\n\n          -  Previous administration of three doses of Synflorix\u2122.\n\n          -  Previous vaccination with a pneumococcal vaccine other than Synflorix\u2122.\n\n          -  Planned administration of another pneumococcal vaccine other than Synflorix\u2122 during\n             the PMS study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "5 Years", 
            "minimum_age": "6 Weeks", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy Sri Lankan infants aged 6 weeks and above and children"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803425", 
            "org_study_id": "116290"
        }, 
        "intervention": {
            "arm_group_label": "Synflorix\u2122 cohort", 
            "description": "Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.", 
            "intervention_name": "Synflorix\u2122 data collection", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Post-marketing surveillance", 
            "Prescribing Information (PI)", 
            "Healthy infants and children", 
            "Streptococcus pneumoniae", 
            "Synflorix\u2122", 
            "Sri Lanka"
        ], 
        "lastchanged_date": "September 5, 2013", 
        "number_of_groups": "1", 
        "official_title": "Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix\u2122) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Sri Lanka: Cosmetics, Devices and Drug Regulatory Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence of solicited local (any intensity) and general (any intensity and causally related) adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "During the 4-day follow-up period (Day 0 to Day 3) following any dose of Synflorix\u2122 and overall"
            }, 
            {
                "measure": "Occurrence of unsolicited AEs", 
                "safety_issue": "No", 
                "time_frame": "During the 31-day period (Day 0 to Day 30) following any dose of Synflorix\u2122 and overall"
            }, 
            {
                "measure": "Occurrence of Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "Throughout the PMS study period, starting at Dose 1 (Visit 1) and ending 31 days (Day 0 to Day 30) after the last dose of Synflorix\u2122 for each subject in the PMS study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803425"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013", 
        "why_stopped": "Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it\n    was concluded GSK will submit local PSURs."
    }
}